查看購物車
  • English
  • Japanese
  • Korean
全球數位乳房斷層攝影市場：按最終用戶、地區和國家分類的分析和預測（2026-2036 年）
市場調查報告書
商品編碼
2042504

全球數位乳房斷層攝影市場：按最終用戶、地區和國家分類的分析和預測（2026-2036 年）

Digital Breast Tomosynthesis Market - A Global and Regional Analysis: Focus on End User, Regional, and Country - Analysis and Forecast, 2026-2036
出版日期: | 出版商: BIS Research | 英文 109 Pages | 商品交期: 1-5個工作天內

價格

數位乳房斷層攝影市場簡介

全球數位乳房斷層攝影市場預計將從 2025 年的 9.257 億美元大幅成長至 2036 年的 28.946 億美元。在 2026 年至 2036 年的預測期內，預計將實現 10.99% 的顯著複合年成長率。

關鍵市場統計數據
預測期 2026-2036
2026 年評估 1,020,700,000 美元
2036 年預測 28.946億美元
複合年成長率 10.99%

隨著醫療機構尋求更精準可靠的乳房攝影影像解決方案以提高乳癌早期檢測和診斷的準確性，數位乳房斷層攝影（DBT）市場正在快速成長。 DBT通常被稱為3D乳房X光攝影，它透過產生乳房組織的多層截面影像來增強傳統影像技術，使放射科醫師能夠更清晰地觀察到標準2D影像中可能遺漏的病灶。隨著全球乳癌篩檢計畫的擴展和公眾意識的提高，DBT正擴大被醫院放射科、癌症中心和先進的診斷機構採用，尤其是在那些對靈敏度和特異性要求極高的環境中。

數位乳房斷層攝影（DBT）技術的不斷進步，透過將高解析度3D影像與合成2D影像相結合、最佳化劑量以及簡化擷取流程，正在變革乳房攝影影像工作流程。這些創新有助於降低複查率、提高病灶定性，並在高通量篩檢和診斷環境中實現更有效率的工作流程。此外，人工智慧影像分析和先進視覺化工具的整合，有助於放射科醫生更快、更一致地解讀影像，進一步提升了DBT的臨床價值。

儘管在擁有完善篩檢基礎設施的先進醫療市場，數位乳房斷層攝影（DBT）技術的普及速度正在加快，但由於系統成本高昂、基礎設施要求高以及人力資源有限，新興地區的成長仍然有限。然而，隨著醫療系統日益重視早期發現和精準診斷，以及技術的普及，DBT有望在乳房攝影過程中發揮越來越重要的作用，並將成為更廣泛的乳房乳房X光攝影市場的一項重大進步。

從最終用戶來看，醫院和門診手術中心是推動市場發展的主要因素。

醫院和門診手術中心 (ASC) 在數位乳房斷層攝影 (DBT) 市場佔主導地位，因為它們是綜合醫療服務的樞紐，能夠緊密協調篩檢、診斷和治療。 DBT 不僅廣泛篩檢，還應用於多種領域，包括診斷檢測、緻密乳房評估、切片檢查前影像檢查和後續觀察評估。這些機構是實施 DBT 系統最實用、最有價值的場所，因為它們能夠在同一醫療網路內實現從影像檢查到高級診斷和治療程序（例如切片檢查中心完全有能力應對這些挑戰。此外，隨著乳癌治療模式向門診和微創方向發展，門診手術中心的角色日益凸顯。門診手術中心可以將 DBT 與當日診斷和治療程序結合。大量的患者以及該系統在整個護理路徑中的多功能應用，提高了系統的利用率和投資回報率，進一步鞏固了 ASC 在 DBT 市場的主導地位。

從地區來看，北美市場處於領先地位。

北美憑藉大規模的篩檢量、完善的報銷體系、廣泛的應用基礎以及較高的醫療機構接受度，正引領著數位乳房斷層攝影（DBT）市場的發展。該地區受益於完善且持續的篩檢體系，尤其是在美國，相關指引建議對40至74歲的女性進行常規篩檢，篩檢方法包括數位乳房X光乳房X光攝影和DBT。加拿大透過省級和地區級的篩檢計畫進一步推動了這項需求，確保了診斷影像服務的穩定和可預測性。此外，優惠的報銷政策，尤其是在美國，降低了病患的經濟負擔，並增強了醫療機構採用和推廣DBT的商業理由。

另一個重要因素是數位乳房斷層攝影（DBT）技術在全部區域已廣泛應用。美國絕大多數乳房X光攝影機構都至少配備了一台DBT設備，這不僅推動了新設備的安裝，也促進了整個網路的升級改造和標準化。乳癌的高發生率以及公共衛生部門持續重視早期檢測，使得對先進影像技術的投資成為必然。此外，北美成熟的醫療基礎設施，包括認證的影像檢查機構和綜合篩檢項目，也使得DBT等先進技術得以快速普及和推廣。因此，在技術成熟和機構對乳癌影像的大力支持下，該地區保持主導地位。

本報告分析了全球數位乳房斷層攝影市場，總結了關鍵趨勢、市場影響因素、法律制度、市場規模趨勢和預測、按各個細分市場和地區/主要國家進行的詳細分析、競爭格局以及主要公司的概況。

目錄

摘要整理

範圍和定義

第1章：全球數位乳房斷層攝影市場：產業展望

  • 市場趨勢
    • 影響分析
    • 數位乳房斷層攝影系統正在發展成為一個完整的乳房攝影診斷平台。
  • 監理情勢
    • 美國
    • 歐洲
    • 亞太地區
  • 市場動態
    • 促進因素、挑戰和機會：當前和未來影響評估
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

第2章：最終用戶

  • 醫院及門診手術中心
  • 診斷中心
    • 其他最終用戶

第3章 區域

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
    • 區域概覽
    • 市場成長促進因素
    • 威脅市場的因素
    • 市場規模及預測

第4章：競爭標竿分析與公司概況

  • 全球數位乳房斷層攝影市場：關鍵策略與趨勢
  • 主要發展分析（依公司分類）
  • 公司簡介
    • Allengers
    • Canon
    • DMS Group
    • FUJIFILM Corporation
    • GE HealthCare
    • Genoray Co., Ltd
    • General Medical Merate SpA
    • Hologic, Inc.
    • Metaltronica SpA
    • Mecanmedical
    • Planmed Oy
    • Siemens Healthineers
    • Shanghai United Imaging Healthcare Co., LTD

第5章：調查方法

Product Code: BHM3671SA

This report can be delivered within 1 working day.

Introduction of the Digital Breast Tomosynthesis Market

The global digital breast tomosynthesis market, initially valued at $925.7 million in 2025, is projected to witness substantial growth, reaching $2,894.6 million by 2036, marking a remarkable compound annual growth rate (CAGR) of 10.99% over the period from 2026 to 2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$1,020.7 Million
2036 Forecast$2,894.6 Million
CAGR10.99%

The digital breast tomosynthesis (DBT) market is gaining momentum as healthcare systems seek more accurate and reliable breast imaging solutions to improve early cancer detection and diagnostic confidence. DBT, often referred to as 3D mammography, enhances conventional imaging by generating layered, cross-sectional views of breast tissue, allowing radiologists to better visualize lesions that may be obscured in standard 2D images. As breast cancer screening programs expand and awareness increases globally, DBT is being increasingly integrated into hospital radiology departments, cancer centers, and advanced diagnostic facilities, particularly in settings where improved sensitivity and specificity are critical.

Ongoing advancements in DBT technology are transforming breast imaging workflows by combining high-resolution 3D imaging with features such as synthesized 2D images, improved dose optimization, and streamlined acquisition processes. These innovations help reduce recall rates, enhance lesion characterization, and improve workflow efficiency in high-volume screening and diagnostic environments. Additionally, the integration of AI-assisted image analysis and advanced visualization tools is further strengthening DBT's clinical value by supporting radiologists in faster and more consistent interpretation.

While adoption is accelerating in developed healthcare markets with established screening infrastructure, growth in emerging regions remains more selective due to higher system costs, infrastructure requirements, and workforce limitations. However, as healthcare systems increasingly prioritize early detection and precision diagnostics, and as technology becomes more accessible, DBT is expected to play an expanding role in breast imaging pathways, positioning it as a key advancement within the broader mammography market.

Market Introduction

The digital breast tomosynthesis (DBT) market is witnessing strong growth as healthcare providers increasingly shift toward more advanced and precise breast imaging technologies for both screening and diagnostic applications. Commonly known as 3D mammography, DBT enhances conventional digital mammography by acquiring multiple low-dose images from different angles to generate a layered, three-dimensional view of breast tissue. This approach significantly improves lesion detection and reduces the masking effect of overlapping tissue, making it particularly valuable in screening programs, diagnostic assessments, and imaging of women with dense breasts. As the global burden of breast cancer continues to rise, DBT is gaining strategic importance as a tool that enhances detection accuracy while supporting more confident and timely clinical decision-making.

Technological advancements are further reinforcing DBT's role across hospitals, specialized breast imaging centers, and organized screening pathways. Modern systems incorporate features such as synthesized 2D imaging, optimized radiation dose, faster acquisition times, AI-enabled workflow support, and integrated biopsy capabilities, all of which improve both clinical outcomes and operational efficiency. These innovations help reduce recall rates, enhance interpretation accuracy, and streamline workflows in high-volume imaging environments. While adoption in some regions remains constrained by high capital costs, reimbursement challenges, infrastructure limitations, and the continued reliance on conventional mammography or ultrasound, the growing focus on early detection, dense-breast evaluation, and precision imaging is expected to drive sustained global expansion of the DBT market.

Industrial Impact

The global digital breast tomosynthesis (DBT) market is creating a strong impact on the breast imaging industry by accelerating the shift from conventional 2D mammography toward more advanced, layered, and clinically informative breast imaging platforms. DBT is increasingly being integrated into breast screening, diagnostic assessment, dense-breast evaluation, and image-guided intervention workflows, making it an important technology across hospitals, breast care centers, diagnostic imaging networks, and oncology-focused facilities. Leading manufacturers are strengthening DBT platforms with capabilities such as synthesized 2D imaging, low-dose acquisition, faster scan times, biopsy guidance, AI-assisted reading support, and improved workflow automation. These advancements are helping providers enhance lesion visibility, reduce the effect of tissue overlap, and improve confidence in breast image interpretation, which is raising the strategic importance of DBT within modern breast care delivery.

From an industry perspective, the expansion of the DBT market is reshaping product development priorities, competitive positioning, and capital investment patterns across the medical imaging sector. Healthcare providers are increasingly assessing DBT systems not only for imaging performance, but also for reading efficiency, interoperability, patient comfort, upgrade flexibility, and compatibility with advanced applications such as tomosynthesis-guided biopsy and intelligent decision-support tools. This is encouraging manufacturers to deliver more integrated, scalable, and workflow-oriented breast imaging platforms that can support both high-volume screening services and complex diagnostic pathways. At the same time, the growing focus on early cancer detection, dense-breast imaging, and replacement of older mammography systems is supporting continued market momentum. By improving diagnostic capability, strengthening breast imaging infrastructure, and enabling a more advanced standard of breast care, DBT is contributing to the ongoing transformation of the global women's health imaging industry.

Market Segmentation

Segmentation 1: By End User

  • Hospitals and Ambulatory Surgical Centers
  • Diagnostics Center
  • Other End User

Hospitals and Ambulatory Surgical Centers Segment to Dominate the Digital Breast Tomosynthesis Market (by End User)

Hospitals and ambulatory surgical centers (ASCs) dominate the digital breast tomosynthesis (DBT) market because they function as integrated care hubs where screening, diagnosis, and intervention are closely linked. DBT is widely used beyond screening, including diagnostic workups, dense-breast evaluation, pre-biopsy imaging, and follow-up assessments. These facilities enable seamless patient flow from imaging to advanced diagnostics and procedures, such as biopsy, within the same network, making them the most practical and high-value adopters of DBT systems. Their dominance is also driven by stronger infrastructure and financial capacity to support advanced imaging technologies. DBT systems require higher capital investment, specialized staff, and integration with IT and radiology workflows, which hospitals and ASCs are better equipped to manage. Additionally, the shift toward outpatient and minimally invasive breast care is increasing the role of ASCs, where DBT can be combined with same-day diagnostic and interventional procedures. High patient volumes and multi-use applications across the care pathway improve system utilization and return on investment, reinforcing their leadership in the DBT market.

Segmentation 2: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of- Latin America
  • Middle East and Africa

North America to Dominate the Digital Breast Tomosynthesis Market (by Region)

North America dominates the digital breast tomosynthesis (DBT) market due to its strong combination of large-scale screening volumes, established reimbursement frameworks, advanced installed base, and high provider readiness. The region benefits from a well-structured and recurring screening ecosystem, particularly in the U.S., where guidelines support routine screening for women aged 40-74 using both digital mammography and DBT. Canada further reinforces this demand through organized screening programs across provinces and territories, ensuring a consistent and predictable imaging pipeline. In addition, favorable reimbursement policies, especially in the U.S., where screening mammography and DBT are supported through established payment pathways, reduce financial barriers for patients and strengthen the business case for providers to adopt and expand DBT usage.

Another key factor is the widespread adoption of DBT across the region, with a majority of U.S. mammography facilities already equipped with at least one DBT unit, driving not only new installations but also replacement cycles and network-wide standardization. This is supported by a high breast cancer burden and sustained public health focus on early detection, which continues to prioritize investment in advanced imaging technologies. Furthermore, North America's mature healthcare infrastructure, including certified imaging facilities and integrated screening programs, enables faster absorption and scaling of advanced modalities like DBT. As a result, the region maintains a leading position, driven by both technological maturity and strong systemic support for breast imaging.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Superior Detection Capability and Reduced Callback Rates Driving the Adoption of Digital Breast Tomosynthesis: Digital breast tomosynthesis (DBT) is increasingly being adopted due to its superior lesion detection capability and lower recall rates compared to conventional 2D mammography. By providing three-dimensional visualization of breast tissue, DBT improves cancer detection-particularly in women with dense breasts while reducing false positives, unnecessary callbacks, and associated patient anxiety and healthcare costs. For example, a 10-year Yale/New Haven Health study summarized by RSNA in September 2024 reported that DBT achieved a higher cancer detection rate than digital mammography (5.3% vs. 4.0%), along with a lower recall rate (7.2% vs. 10.6%) and fewer advanced cancers at diagnosis (32.7% vs. 43.6%).

Similarly, a JAMA Oncology study published in May 2025 analyzing over 200,000 women with a family history of breast cancer found that DBT significantly reduced recall rates and improved specificity compared to digital mammography, with an adjusted recall reduction of 1.51 percentage points. The study also highlighted stronger performance in women with dense breast tissue, showing improved detection of early-stage invasive cancers with favorable prognostic features and a reduction in advanced cancer incidence. Collectively, these findings reinforce DBT's clinical advantage, supporting its growing integration into breast cancer screening and diagnostic pathways.

Market Challenges

High Cost of DBT Systems: The high cost of digital breast tomosynthesis (DBT) systems remains a key constraint on market expansion, limiting adoption across both advanced and emerging healthcare settings. Although DBT offers clear clinical benefits, its upfront capital cost typically ranges from around $90,000 for basic configurations to over $300,000 for advanced, AI-enabled systems, posing a significant barrier, particularly for small and mid-sized facilities with constrained budgets.

This challenge is further intensified by the total cost of ownership, which can rise to approximately $350,000-$700,000 over an 8-year lifecycle due to ongoing expenses such as maintenance, software upgrades, and component replacements. As a result, healthcare providers often extend equipment replacement cycles and delay transitioning from 2D mammography to DBT, especially in cost-sensitive markets. Additionally, high capital requirements restrict broader access in low- and middle-income countries and limit adoption in community-based settings even within developed regions, ultimately slowing large-scale penetration of DBT despite strong clinical demand.

Market Opportunities

Shift from Age-Based to Risk-Stratified, Personalized Screening: The global shift from age-based breast cancer screening toward risk-stratified, personalized screening models presents a significant growth opportunity for digital breast tomosynthesis (DBT). This transition is redefining mammography from a routine, age-driven test into a more targeted tool for risk assessment and clinical decision-making. Healthcare systems are increasingly incorporating factors such as breast density, family history, genetic risk, and prior findings into screening pathways, supported by evolving clinical guidelines and regulatory emphasis on breast density notification. As a result, screening is becoming more individualized, moving away from uniform protocols toward tailored imaging strategies.

Importantly, this evolution strengthens rather than replaces the role of DBT. Personalized screening still relies on mammographic imaging as a core component but demands higher diagnostic accuracy, particularly for women with dense breasts or moderate risk profiles. This is driving preference for advanced imaging technologies like DBT over conventional 2D systems. Large-scale studies such as the WISDOM and MyPeBS trials further reinforce this shift, demonstrating how risk-based approaches can alter screening pathways and support broader real-world adoption. Consequently, DBT is increasingly positioned as a key enabler of precision breast imaging within next-generation screening frameworks.

How can this report add value to an organization?

Growth/Marketing Strategy: Market growth is driven by strategic partnerships, hospital and clinic network expansions, and alignment with national and regional breast cancer screening initiatives. OEMs are targeting hospitals, specialized breast centers, and diagnostic chains, while also entering emerging economies where unmet demand for advanced imaging is high. Mobile and retrofit DBT solutions help broaden adoption, particularly in areas with limited infrastructure, supporting both screening and diagnostic workflows.

Competitive Strategy: The DBT market is highly competitive, with OEMs differentiating through high-resolution imaging, AI-enabled diagnostic tools, and workflow efficiency. Success increasingly depends on providing integrated solutions that combine hardware, software, and analytics to reduce radiologist workload and improve diagnostic confidence. Key competitive advantages are clinical accuracy, operational reliability, interoperability with PACS and EMR systems, and the ability to manage high-volume, multi-modality breast imaging pathways.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for the global market size estimation, 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
  • The scope of the report is based on comprehensive inputs from industry experts across various sectors, including hospitals, diagnostic laboratories, imaging centers, and research institutions.
  • The market contribution of DBT systems is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
  • Revenues from companies have been sourced from their annual reports for FY2024 and FY2025. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on the existing DBT systems. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts and key stakeholders across the healthcare and radiography ecosystem, including DBT manufacturers (OEMs), medical device companies, radiology service providers, and healthcare institutions. Stakeholders such as hospitals, imaging centers, and screening programs have been consulted to validate adoption trends, system-level integration, and clinical utility specific to DBT systems. Respondents, including CEOs, vice presidents, product and marketing directors, and technology and innovation leaders, have been interviewed to obtain and verify both qualitative and quantitative insights for this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Allengers
  • DMS Group
  • FUJIFILM Corporation
  • GE Healthcare
  • Genoray Co., Ltd.
  • Hologic, Inc.
  • IMS Giotto S.p.A.
  • Metaltronica S.p.A.
  • Planmed Oy
  • Siemens Healthineers
  • Shanghai United Imaging Healthcare Co., Ltd.

Table of Contents

Executive Summary

Scope and Definition

1 Global Digital Breast Tomosynthesis Market: Industry Outlook

  • 1.1 Market Trends
    • 1.1.1 Impact Analysis
    • 1.1.2 Digital Breast Tomosynthesis Systems are Evolving into Full Breast-Imaging Platforms
  • 1.2 Regulatory Landscape
    • 1.2.1 U.S.
    • 1.2.2 Europe
    • 1.2.3 Asia-Pacific
      • 1.2.3.1 China
      • 1.2.3.2 Japan
  • 1.3 Market Dynamics
    • 1.3.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 1.3.2 Market Drivers
      • 1.3.2.1 Rising Breast-Cancer Burden and Stronger Focus on Early Detection
      • 1.3.2.2 Superior Detection Capability and Reduced Callback Rates Driving the Adoption of Digital Breast Tomosynthesis
    • 1.3.3 Market Challenges
      • 1.3.3.1 High Capital and Maintenance Cost
    • 1.3.4 Market Opportunities
      • 1.3.4.1 Shift from Age-Based to Risk-Stratified, Personalized Screening

2 End User

  • 2.1 Hospitals and Ambulatory Surgical Centers
  • 2.2 Diagnostics Centers
    • 2.2.1 Other End Users

3 Region

  • 3.1 North America
    • 3.1.1 Regional Overview
    • 3.1.2 Driving Factors for Market Growth
    • 3.1.3 Factors Challenging the Market
    • 3.1.4 Market Sizing and Forecast
      • 3.1.4.1 U.S.
        • 3.1.4.1.1 Country Overview
        • 3.1.4.1.2 Driving Factors for Market Growth
        • 3.1.4.1.3 Factors Challenging the Market
        • 3.1.4.1.4 Market Sizing and Forecast
      • 3.1.4.2 Canada
        • 3.1.4.2.1 Country Overview
        • 3.1.4.2.2 Driving Factors for Market Growth
        • 3.1.4.2.3 Factors Challenging the Market
        • 3.1.4.2.4 Market Sizing and Forecast
  • 3.2 Europe
    • 3.2.1 Regional Overview
    • 3.2.2 Driving Factors for Market Growth
    • 3.2.3 Factors Challenging the Market
    • 3.2.4 Market Sizing and Forecast
      • 3.2.4.1 U.K.
        • 3.2.4.1.1 Country Overview
        • 3.2.4.1.2 Driving Factors for Market Growth
        • 3.2.4.1.3 Factors Challenging the Market
        • 3.2.4.1.4 Market Sizing and Forecast
      • 3.2.4.2 Germany
        • 3.2.4.2.1 Country Overview
        • 3.2.4.2.2 Driving Factors for Market Growth
        • 3.2.4.2.3 Factors Challenging the Market
        • 3.2.4.2.4 Market Sizing and Forecast
      • 3.2.4.3 France
        • 3.2.4.3.1 Country Overview
        • 3.2.4.3.2 Driving Factors for Market Growth
        • 3.2.4.3.3 Factors Challenging the Market
        • 3.2.4.3.4 Market Sizing and Forecast
      • 3.2.4.4 Italy
        • 3.2.4.4.1 Country Overview
        • 3.2.4.4.2 Driving Factors for Market Growth
        • 3.2.4.4.3 Factors Challenging the Market
        • 3.2.4.4.4 Market Sizing and Forecast
      • 3.2.4.5 Spain
        • 3.2.4.5.1 Country Overview
        • 3.2.4.5.2 Driving Factors for Market Growth
        • 3.2.4.5.3 Factors Challenging the Market
        • 3.2.4.5.4 Market Sizing and Forecast
      • 3.2.4.6 Rest-of-the- Europe
        • 3.2.4.6.1 Country Overview
        • 3.2.4.6.2 Driving Factors for Market Growth
        • 3.2.4.6.3 Factors Challenging the Market
        • 3.2.4.6.4 Market Sizing and Forecast
  • 3.3 Asia-Pacific
    • 3.3.1 Regional Overview
    • 3.3.2 Driving Factors for Market Growth
    • 3.3.3 Factors Challenging the Market
    • 3.3.4 Market Sizing and Forecast
      • 3.3.4.1 China
        • 3.3.4.1.1 Country Overview
        • 3.3.4.1.2 Driving Factors for Market Growth
        • 3.3.4.1.3 Factors Challenging the Market
        • 3.3.4.1.4 Market Sizing and Forecast
      • 3.3.4.2 Japan
        • 3.3.4.2.1 Country Overview
        • 3.3.4.2.2 Driving Factors for Market Growth
        • 3.3.4.2.3 Factors Challenging the Market
        • 3.3.4.2.4 Market Sizing and Forecast
      • 3.3.4.3 India
        • 3.3.4.3.1 Country Overview
        • 3.3.4.3.2 Driving Factors for Market Growth
        • 3.3.4.3.3 Factors Challenging the Market
        • 3.3.4.3.4 Market Sizing and Forecast
      • 3.3.4.4 Australia
        • 3.3.4.4.1 Country Overview
        • 3.3.4.4.2 Driving Factors for Market Growth
        • 3.3.4.4.3 Factors Challenging the Market
        • 3.3.4.4.4 Market Sizing and Forecast
      • 3.3.4.5 South Korea
        • 3.3.4.5.1 Country Overview
        • 3.3.4.5.2 Driving Factors for Market Growth
        • 3.3.4.5.3 Factors Challenging the Market
        • 3.3.4.5.4 Market Sizing and Forecast
      • 3.3.4.6 Rest-of-the-Asia-Pacific
        • 3.3.4.6.1 Country Overview
        • 3.3.4.6.2 Driving Factors for Market Growth
        • 3.3.4.6.3 Factors Challenging the Market
        • 3.3.4.6.4 Market Sizing and Forecast
  • 3.4 Latin America
    • 3.4.1 Regional Overview
    • 3.4.2 Driving Factors for Market Growth
    • 3.4.3 Factors Challenging the Market
    • 3.4.4 Market Sizing and Forecast
      • 3.4.4.1 Brazil
        • 3.4.4.1.1 Country Overview
        • 3.4.4.1.2 Driving Factors for Market Growth
        • 3.4.4.1.3 Factors Challenging the Market
        • 3.4.4.1.4 Market Sizing and Forecast
      • 3.4.4.2 Mexico
        • 3.4.4.2.1 Country Overview
        • 3.4.4.2.2 Driving Factors for Market Growth
        • 3.4.4.2.3 Factors Challenging the Market
        • 3.4.4.2.4 Market Sizing and Forecast
      • 3.4.4.3 Rest-of-Latin America
        • 3.4.4.3.1 Country Overview
        • 3.4.4.3.2 Driving Factors for Market Growth
        • 3.4.4.3.3 Factors Challenging the Market
        • 3.4.4.3.4 Market Sizing and Forecast
  • 3.5 Middle-East & Africa
    • 3.5.1 Regional Overview
    • 3.5.2 Driving Factors for Market Growth
    • 3.5.3 Factors Challenging the Market
    • 3.5.4 Market Sizing and Forecast

4 Competitive Benchmarking and Company Profiles

  • 4.1 Global Digital Breast Tomosynthesis Market, Key Strategies and Developments, January 2023-April 2026
  • 4.2 Key Developments Analysis (by Company), January 2023-April 2026
  • 4.3 Company Profiles
    • 4.3.1 Allengers
      • 4.3.1.1 Overview
      • 4.3.1.2 Top Products
      • 4.3.1.3 Key Personnel
      • 4.3.1.4 Analyst View
    • 4.3.2 Canon
      • 4.3.2.1 Overview
      • 4.3.2.2 Top Products
      • 4.3.2.3 Key Personnel
      • 4.3.2.4 Analyst View
    • 4.3.3 DMS Group
      • 4.3.3.1 Overview
      • 4.3.3.2 Top Products
      • 4.3.3.3 Key Personnel
      • 4.3.3.4 Analyst View
    • 4.3.4 FUJIFILM Corporation
      • 4.3.4.1 Overview
      • 4.3.4.2 Top Products
      • 4.3.4.3 Key Personnel
      • 4.3.4.4 Analyst View
    • 4.3.5 GE HealthCare
      • 4.3.5.1 Overview
      • 4.3.5.2 Top Products
      • 4.3.5.3 Key Personnel
      • 4.3.5.4 Analyst View
    • 4.3.6 Genoray Co., Ltd
      • 4.3.6.1 Overview
      • 4.3.6.2 Top Products
      • 4.3.6.3 Key Personnel
      • 4.3.6.4 Analyst View
    • 4.3.7 General Medical Merate S.p.A.
      • 4.3.7.1 Overview
      • 4.3.7.2 Top Products
      • 4.3.7.3 Key Personnel
      • 4.3.7.4 Analyst View
    • 4.3.8 Hologic, Inc.
      • 4.3.8.1 Overview
      • 4.3.8.2 Top Products
      • 4.3.8.3 Key Personnel
      • 4.3.8.4 Analyst View
    • 4.3.9 Metaltronica S.p.A.
      • 4.3.9.1 Overview
      • 4.3.9.2 Top Products
      • 4.3.9.3 Key Personnel
      • 4.3.9.4 Analyst View
    • 4.3.10 Mecanmedical
      • 4.3.10.1 Overview
      • 4.3.10.2 Top Products
      • 4.3.10.3 Key Personnel
      • 4.3.10.4 Analyst View
    • 4.3.11 Planmed Oy
      • 4.3.11.1 Overview
      • 4.3.11.2 Top Products
      • 4.3.11.3 Key Personnel
      • 4.3.11.4 Analyst View
    • 4.3.12 Siemens Healthineers
      • 4.3.12.1 Overview
      • 4.3.12.2 Top Products
      • 4.3.12.3 Key Personnel
      • 4.3.12.4 Analyst View
    • 4.3.13 Shanghai United Imaging Healthcare Co., LTD
      • 4.3.13.1 Overview
      • 4.3.13.2 Top Products
      • 4.3.13.3 Key Personnel
      • 4.3.13.4 Analyst View

5 Research Methodology

  • 5.1 Data Sources
    • 5.1.1 Primary Data Sources
    • 5.1.2 Secondary Data Sources
    • 5.1.3 Data Triangulation
  • 5.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Digital Breast Tomosynthesis Market (by Scenario), $Million, 2025, 2026, and 2036
  • Figure 2: Global Digital Breast Tomosynthesis Market, 2025 and 2036
  • Figure 3: Global Digital Breast Tomosynthesis Market (by Country), $Million, 2025
  • Figure 4: Global Digital Breast Tomosynthesis Market Snapshot
  • Figure 5: Global Digital Breast Tomosynthesis Market, $Million, 2025 and 2036
  • Figure 6: Digital Breast Tomosynthesis Market (by End User), $Million, 2025, 2030, and 2036
  • Figure 7: Global Digital Breast Tomosynthesis Market (by End User), $Million, 2025, 2030, and 2036
  • Figure 8: Global Digital Breast Tomosynthesis Market (Hospitals and Ambulatory Surgical Centers), $Million, 2024-2036
  • Figure 9: Global Digital Breast Tomosynthesis Market (Diagnostics Centers), $Million, 2024-2036
  • Figure 10: Global Digital Breast Tomosynthesis Market (Other End Users), $Million, 2024-2036
  • Figure 11: North America Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 12: U.S. Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 13: Canada Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 14: Europe Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 15: U.K. Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 16: Germany Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 17: France Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 18: Italy Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 19: Spain Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 20: Rest-of-Europe Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 21: Asia-Pacific Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 22: China Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 23: Japan Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 24: India Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 25: Australia Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 26: South Korea Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 27: Rest-of-Asia-Pacific Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 28: Latin America Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 29: Brazil Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 30: Mexico Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 31: Rest-of- Latin America Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 32: Middle East and Africa Digital Breast Tomosynthesis Market, $Million, 2024-2036
  • Figure 33: Global Digital Breast Tomosynthesis Market, Key Strategies and Developments, January 2023-April 2026
  • Figure 34: Data Triangulation
  • Figure 35: Top-Down and Bottom-Up Approach
  • Figure 36: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Cost of Intermediate Digital Breast Tomosynthesis-Capable Systems
  • Table 3: Cost of Premium Advanced Digital Breast Tomosynthesis with AI
  • Table 4: Global Digital Breast Tomosynthesis Market (by Region), $Million, 2024-2036
  • Table 5: North America Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 6: U.S. Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 7: Canada Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 8: Europe Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 9: U.K. Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 10: Germany Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 11: France Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 12: Italy Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 13: Spain Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 14: Rest-of-Europe Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 15: Asia-Pacific Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 16: China Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 17: Japan Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 18: India Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 19: Australia Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 20: South Korea Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 21: Rest-of-Asia-Pacific Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 22: Latin America Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 23: Brazil Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 24: Mexico Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 25: Rest-of-Latin America Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 26: Middle East and Africa Digital Breast Tomosynthesis Market (End Users), $Million, 2024-2036
  • Table 27: Global Digital Breast Tomosynthesis Market, Key Strategies and Developments (by Company), January 2023-April 2026